evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

51 questions · 56 findings · 27 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 2 · 3.6%GRADE not reported 3 · 5.4%Very low 9 · 16.1%Low 19 · 33.9%Moderate 17 · 30.4%High 6 · 10.7%

Bortezomib vs no bortezomib

Adverse effects (cardiac) · All patients with a diagnosis of multiple myeloma

Bortezomib leads to higher adverse Events: Cardiac Disorders compared with no bortezomib (high certainty).

2 findings from 1 review

Bortezomib vs no bortezomib

Adverse Events: Peripheral Neuropathy · All patients with a diagnosis of multiple myeloma

Bortezomib probably leads to higher adverse Events: Peripheral Neuropathy compared with no bortezomib (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Daratumumab plus standard therapy vs usual care

Serious adverse events at longest · people with newly diagnosed multiple myeloma ineligible for transplant

Summary of findings table ‐ Daratumumab plus standard therapy probably leads to higher serious adverse events (longest available compared with standard therapy (moderate certainty).

1 finding from 1 review

Ocrelizumab vs interferon beta‐1a

Number of participants with any adverse events · patients with relapsing‐remitting multiple sclerosis

Ocrelizumab showed no clear difference in number of participants with any adverse events compared with interferon beta‐1a (moderate certainty).

1 finding from 1 review

Ocrelizumab vs placebo

Number of participants with any adverse events · primary progressive multiple sclerosis

Ocrelizumab probably leads to higher number of participants with any adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Alemtuzumab 24 mg vs interferon beta‐1a

Number of participants with serious adverse events · patients with relapsing‐remitting multiple sclerosis

Alemtuzumab 24 mg showed no clear difference in number of participants with serious adverse events compared with interferon beta 1a (moderate certainty).

1 finding from 1 review

Alemtuzumab 12 mg vs interferon beta‐1a

Number of participants with serious adverse events · patients with relapsing‐remitting multiple sclerosis

Alemtuzumab 12 mg showed no clear difference in number of participants with serious adverse events compared with interferon beta 1a (moderate certainty).

1 finding from 1 review

Intervention not reported

The number of patients with serious adverse events · patients with relapsing‐remitting multiple sclerosis

The intervention showed no clear difference in the number of patients with serious adverse events (low certainty).

1 finding from 1 review

Summary of findings table ‐ Daratumumab plus standard therapy vs usual care

Adverse events (grade ≥ 3) · people with newly diagnosed multiple myeloma ineligible for transplant

Summary of findings table ‐ Daratumumab plus standard therapy showed no clear difference in adverse events (CTCAE grade ≥ 3) (longest available compared with standard therapy (moderate certainty).

1 finding from 1 review

Ocrelizumab vs placebo

Number of participants with any serious adverse events · primary progressive multiple sclerosis

Ocrelizumab showed no clear difference in number of participants with any serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Ocrelizumab vs interferon beta‐1a

Number of participants with any serious adverse events · patients with relapsing‐remitting multiple sclerosis

Ocrelizumab showed no clear difference in number of participants with any serious adverse events compared with interferon beta‐1a (low certainty).

1 finding from 1 review

Plerixafor vs placebo

Adverse events (during stem cell mobilisation and collection) · People with haematopoietic stem cell mobilisation for autologous transplantation in malignant lymphoma or multiple myeloma

Plerixafor showed no clear difference in adverse events (during stem cell mobilisation and collection) compared with placebo (high certainty).

1 finding from 1 review

Summary of findings table ‐ Daratumumab plus standard therapy vs usual care

Adverse events: infections (CTCAE grade ≥ 3) (longest available · people with newly diagnosed multiple myeloma ineligible for transplant

Summary of findings table ‐ Daratumumab plus standard therapy probably leads to higher adverse events: infections (CTCAE grade ≥ 3) (longest available compared with standard therapy (moderate certainty).

1 finding from 1 review

Rituximab vs placebo

Serious adverse events measured by clinical assessment over 12 months · relapsing multiple sclerosis

It is very uncertain whether rituximab as 'switching' changes serious adverse events measured by clinical assessment over 12 months compared with placebo (very low certainty).

1 finding from 1 review

Rituximab vs placebo

Serious adverse events measured by clinical assessment over 12 months · primary progressive multiple sclerosis

Rituximab as 'first choice' showed no clear difference in serious adverse events measured by clinical assessment over 28 months compared with placebo (low certainty).

1 finding from 1 review

Exercise vs control immediately post intervention

Adverse events The timing of measurement was post‐intervention for all studies · people with multiple sclerosis

Exercise showed no clear difference in adverse events The timing of measurement was post‐intervention for… compared with control (post‐intervention) (low certainty).

1 finding from 1 review

Ocrelizumab vs interferon beta‐1a

Number of participants with adverse events leading to study discontinuation · patients with relapsing‐remitting multiple sclerosis

Ocrelizumab may leads to lower number of participants experiencing treatment discontinuation caused… compared with interferon beta‐1a (low certainty).

1 finding from 1 review

Alemtuzumab 24 mg vs interferon beta‐1a

Number of participants with adverse events leading to study discontinuation · patients with relapsing‐remitting multiple sclerosis

It is very uncertain whether alemtuzumab 24 mg changes number of participants experiencing treatment discontinuation caused… compared with interferon beta 1a (very low certainty).

1 finding from 1 review

Alemtuzumab 12 mg vs interferon beta‐1a

Number of participants with adverse events leading to study discontinuation · patients with relapsing‐remitting multiple sclerosis

Alemtuzumab 12 mg may leads to lower number of participants experiencing treatment discontinuation caused… compared with interferon beta 1a (low certainty).

1 finding from 1 review

Alemtuzumab 12 mg vs interferon beta‐1a

Adverse events, including serious adverse events Assessed by: number of participants with ≥ 1 event · adults with relapsing–remitting multiple sclerosis

Alemtuzumab 12 mg showed no clear difference in adverse events, including serious events Assessed by: number of… compared with interferon beta‐1a (low certainty).

1 finding from 1 review